For the fourth quarter of 2007, Baxter expects sales growth, excluding the impact of foreign exchange, of 2 to 3 percent, and earnings per diluted share, before any special items, of $0.72 to $0.74. Excluding the Transfusion Therapies business from both the 2006 and 2007 fourth quarters, sales growth (excluding foreign exchange) is expected to approximate 7 percent.
A webcast of Baxter's third quarter conference call for investors can be accessed live from a link on the company's website at http://www.baxter.com beginning at 7:30 a.m. CDT on October 18, 2007. Please visit Baxter's website for more information regarding this and future investor events and webcasts, including investor presentations.
Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
This release includes forward-looking statements concerning the
company's financial results. The statements are based on assumptions about
many important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking statements:
demand for and market acceptance risks for new and existing products, such
as ADVATE, and other technologies; future actions of regulatory bodies and
other governmental authorities, including the FDA and forei
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved